April 1st 2025
Vanda Pharmaceuticals has submitted an NDA for approval of Bysanti for the treatment of acute bipolar I disorder and schizophrenia.
FDA Approves Erzofri for the Treatment of Schizophrenia and Schizoaffective Disorder
July 30th 2024The US Food and Drug Administration has approved Erzofri, a paliperidone palmitate extended-release injectable suspension for the treatment of adults with schizophrenia and schizoaffective disorder.
Read More
Approved sNDA: Wakix for Treatment of Excessive Daytime Sleepiness in Youth With Narcolepsy
June 24th 2024The FDA has approved its supplemental New Drug Application for Wakix tablets for the treatment of excessive daytime sleepiness in pediatric patients aged 6 years and older with narcolepsy.
Read More